- Market Capitalization, $K 21,379,442
- Shares Outstanding, K 660,675
- Annual Sales, $ 2,067 M
- Annual Income, $ 781,920 K
- 60-Month Beta 1.01
- Price/Sales 10.28
- Price/Cash Flow 24.77
- Price/Book 4.55
|Period||Period Low||Period High||Performance|
| || |
+1.28 (+4.13%)since 11/08/23
| || |
-5.51 (-14.58%)since 09/08/23
| || |
-13.56 (-29.58%)since 12/08/22
The growing adoption of AI technologies by biopharmaceutical companies and the increasing government initiatives worldwide are expected to boost the biotech industry. Therefore, it could be wise to buy...
The biotech industry is well-positioned for robust growth thanks to the increasing demand for effective treatments for chronic diseases and the need to serve an aging population. To capitalize on the favorable...
The biotech industry’s expansion stems from advancements in bio-medical drug development and cutting-edge technology. Given these factors, prominent biotech stocks Inovio Pharmaceuticals (INO), Surrozen...
The biotech stock's lead therapy is looking at some competition.
Zai Lab's shares benefited from positive clinical trial news.
Find out if AbbVie can overcome sinking sales of its top-selling product.
The company has been a strong value stock but faces big changes this year.
Due to the emergence of new technologies and the introduction of generic medicines, the pharma industry seems well-positioned to witness growth. While pharma stocks should benefit from the industry tailwinds,...
Technological improvements, government, and private investment, and favorable regulatory policies are propelling the biotech industry’s growth and offering breakthrough cures and products. With the industry...
In May, the FDA approved epcoritamab, developed by AbbVie and Genmab, as a treatment for a type of blood cancer.
|3rd Resistance Point||33.09|
|2nd Resistance Point||32.87|
|1st Resistance Point||32.57|
|1st Support Level||32.06|
|2nd Support Level||31.85|
|3rd Support Level||31.55|